IBDEI14C ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,18148,1,3,0)
 ;;=3^DM Type 1 w/ Diab Foot Ulcer
 ;;^UTILITY(U,$J,358.3,18148,1,4,0)
 ;;=4^E10.621
 ;;^UTILITY(U,$J,358.3,18148,2)
 ;;=^5002616
 ;;^UTILITY(U,$J,358.3,18149,0)
 ;;=E10.622^^61^804^28
 ;;^UTILITY(U,$J,358.3,18149,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18149,1,3,0)
 ;;=3^DM Type 1 w/ Oth Skin Ulcer
 ;;^UTILITY(U,$J,358.3,18149,1,4,0)
 ;;=4^E10.622
 ;;^UTILITY(U,$J,358.3,18149,2)
 ;;=^5002617
 ;;^UTILITY(U,$J,358.3,18150,0)
 ;;=E10.51^^61^804^32
 ;;^UTILITY(U,$J,358.3,18150,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18150,1,3,0)
 ;;=3^DM Type 1 w/ Periph Angiopathy w/o Gangrene
 ;;^UTILITY(U,$J,358.3,18150,1,4,0)
 ;;=4^E10.51
 ;;^UTILITY(U,$J,358.3,18150,2)
 ;;=^5002610
 ;;^UTILITY(U,$J,358.3,18151,0)
 ;;=E10.52^^61^804^31
 ;;^UTILITY(U,$J,358.3,18151,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18151,1,3,0)
 ;;=3^DM Type 1 w/ Periph Angiopathy w/ Gangrene
 ;;^UTILITY(U,$J,358.3,18151,1,4,0)
 ;;=4^E10.52
 ;;^UTILITY(U,$J,358.3,18151,2)
 ;;=^5002611
 ;;^UTILITY(U,$J,358.3,18152,0)
 ;;=E11.00^^61^805^19
 ;;^UTILITY(U,$J,358.3,18152,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18152,1,3,0)
 ;;=3^DM Type 2 w/ Hyperosmolarity w/o NKHHC
 ;;^UTILITY(U,$J,358.3,18152,1,4,0)
 ;;=4^E11.00
 ;;^UTILITY(U,$J,358.3,18152,2)
 ;;=^5002627
 ;;^UTILITY(U,$J,358.3,18153,0)
 ;;=E11.01^^61^805^18
 ;;^UTILITY(U,$J,358.3,18153,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18153,1,3,0)
 ;;=3^DM Type 2 w/ Hyperosmolarity w/ Coma
 ;;^UTILITY(U,$J,358.3,18153,1,4,0)
 ;;=4^E11.01
 ;;^UTILITY(U,$J,358.3,18153,2)
 ;;=^5002628
 ;;^UTILITY(U,$J,358.3,18154,0)
 ;;=E11.21^^61^805^7
 ;;^UTILITY(U,$J,358.3,18154,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18154,1,3,0)
 ;;=3^DM Type 2 w/ Diab Nephropathy
 ;;^UTILITY(U,$J,358.3,18154,1,4,0)
 ;;=4^E11.21
 ;;^UTILITY(U,$J,358.3,18154,2)
 ;;=^5002629
 ;;^UTILITY(U,$J,358.3,18155,0)
 ;;=E11.22^^61^805^3
 ;;^UTILITY(U,$J,358.3,18155,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18155,1,3,0)
 ;;=3^DM Type 2 w/ Diab CKD
 ;;^UTILITY(U,$J,358.3,18155,1,4,0)
 ;;=4^E11.22
 ;;^UTILITY(U,$J,358.3,18155,2)
 ;;=^5002630
 ;;^UTILITY(U,$J,358.3,18156,0)
 ;;=E11.39^^61^805^28
 ;;^UTILITY(U,$J,358.3,18156,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18156,1,3,0)
 ;;=3^DM Type 2 w/ Oth Diab Ophth Compl
 ;;^UTILITY(U,$J,358.3,18156,1,4,0)
 ;;=4^E11.39
 ;;^UTILITY(U,$J,358.3,18156,2)
 ;;=^5002643
 ;;^UTILITY(U,$J,358.3,18157,0)
 ;;=E11.41^^61^805^6
 ;;^UTILITY(U,$J,358.3,18157,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18157,1,3,0)
 ;;=3^DM Type 2 w/ Diab Mononeuropathy
 ;;^UTILITY(U,$J,358.3,18157,1,4,0)
 ;;=4^E11.41
 ;;^UTILITY(U,$J,358.3,18157,2)
 ;;=^5002645
 ;;^UTILITY(U,$J,358.3,18158,0)
 ;;=E11.42^^61^805^13
 ;;^UTILITY(U,$J,358.3,18158,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18158,1,3,0)
 ;;=3^DM Type 2 w/ Diab Polyneuropathy
 ;;^UTILITY(U,$J,358.3,18158,1,4,0)
 ;;=4^E11.42
 ;;^UTILITY(U,$J,358.3,18158,2)
 ;;=^5002646
 ;;^UTILITY(U,$J,358.3,18159,0)
 ;;=E11.43^^61^805^2
 ;;^UTILITY(U,$J,358.3,18159,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18159,1,3,0)
 ;;=3^DM Type 2 w/ Diab Autonomic Polyneuropathy
 ;;^UTILITY(U,$J,358.3,18159,1,4,0)
 ;;=4^E11.43
 ;;^UTILITY(U,$J,358.3,18159,2)
 ;;=^5002647
 ;;^UTILITY(U,$J,358.3,18160,0)
 ;;=E11.44^^61^805^1
 ;;^UTILITY(U,$J,358.3,18160,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18160,1,3,0)
 ;;=3^DM Type 2 w/ Diab Amyotrophy
